{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiepr5fgv5d6bzocska5cn6bvtbhcmmen4onyzzgg6jcvhctqrasli",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgmwus5alrh2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifxiju6q5qrlsxx2amxgf3m7aubwff4bkr3uymlybznzm5kddnkjq"
    },
    "mimeType": "image/jpeg",
    "size": 60274
  },
  "path": "/2026/03/09/fda-cuts-back-advisory-meetings-controversial-decisions-grow/?utm_campaign=rss",
  "publishedAt": "2026-03-09T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "A STAT Examination",
    "Biotech",
    "Health",
    "Pharma",
    "Politics",
    "Prescription Politics",
    "biotechnology",
    "drug development",
    "FDA",
    "Pharmaceuticals",
    "Policy",
    "STAT+"
  ],
  "textContent": "The FDA is cutting back on public advisory committee meetings, even as the public and other stakeholders seek more transparency.",
  "title": "STAT+: As controversial decisions mount, FDA shuns public advisory meetings",
  "updatedAt": "2026-03-09T02:11:48.000Z"
}